Patent cliffs & loss of exclusivity
CellTrans develops, manufactures, and commercializes FDA-approved cellular therapies and novel bioengineered technologies for the treatment of diabetes and other endocrine disorders.
| Official Website | http://celltransinc.com |
|---|
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.